FDA recall record

Cystaran recall — FDA D-0034-2021

Subpotent Drug: Product testing identified a decreased level of the active ingredient, Cysteamine HCl.

Class IIIclassification
D-0034-2021official record ID
Oct 21, 2020report date

Recall record at a glance

Official recordD-0034-2021
CategoryDrug Recalls
ClassificationClass III
FDA record statusTerminated
Recalling firmLeadiant Biosciences, Inc.
Report dateOct 21, 2020
Recall initiation dateSep 24, 2020
Quantity1380 bottles
LocationGaithersburg, MD, United States

Official product description

Cystaran (cysteamine ophthalmic solution) 0.44%, For Ophthalmic Use Only, 15 mL bottle, Sterile, Rx Only, Manufactured by Hi-Tech Pharmacal Co Inc., Amityville, NY 11701 for Leadiant Biosciences, Inc., Gaithersburg, MD 20878, NDC 54482-020-01

Why the product was recalled

Subpotent Drug: Product testing identified a decreased level of the active ingredient, Cysteamine HCl.

Distribution information

PA and Italy

How to read the classification

FDA Class III generally covers situations in which use of or exposure to the product is not likely to cause adverse health consequences. The classification displayed here is taken from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.